Stryker Corporation (NYSE:SYK) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 27, Matthew O’Brien from Piper Sandler reiterated his Overweight rating on Stryker Corporation (NYSE:SYK) with a price target of $420. His target price estimate represents over 17% upside for investors. O’Brien shed light on the company’s new handheld orthopedic robot, identified as Mako RPS, after connecting with a physician who had seen the product. According to the initial stu ...

Stryker Corporation (SYK) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $4.47, which beat the Zacks Consensus Estimate of $4.40 by 1.6%. The bottom line also improved 11.5% year over year. Our model estimate for the metric was pegged at $3.15 per share.GAAP EPS was $2.22, up 2.8% from the year-ago quarter’s level.For the full year, adjusted EPS gained 11.8% to $13.63. GAAP EPS was $8.40, up 8.2% from the year-ago level.Revenue DetailsRevenues totaled $7.17 billion, which beat the Zacks C ...

For the quarter ended December 2025, Stryker (SYK) reported revenue of $7.17 billion, up 11.4% over the same period last year. EPS came in at $4.47, compared to $4.01 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $7.13 billion, representing a surprise of +0.61%. The company delivered an EPS surprise of +1.71%, with the consensus EPS estimate being $4.40.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Medical equipment maker Stryker raised its full-year profit forecast on Thursday, banking on strong sales of its implants and other medical devices. ...

Stryker (NYSE:SYK) Q4 2025 Earnings call January 29, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJason Beach - VP of Finance and Head of Investor RelationsJoanne Wuensch - Managing DirectorKevin Lobo - Chair and CEOPatrick Wood - Managing DirectorPreston Wells - CFORichard Newitter - Managing DirectorConference Call ParticipantsCaitlin Roberts - AnalystChris Pasquale - AnalystDanielle Antalffy - AnalystDrew Ranieri - AnalystJeff Johnson - AnalystLarry Biegelsen - Senior AnalystMatt M ...

Stryker (NYSE:SYK) Q4 2025 Earnings call January 29, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJason Beach - VP of Finance and Head of Investor RelationsJoanne Wuensch - Managing DirectorKevin Lobo - Chair and CEOPatrick Wood - Managing DirectorPreston Wells - CFORichard Newitter - Managing DirectorConference Call ParticipantsCaitlin Roberts - AnalystChris Pasquale - Senior Analyst for Medical Devices & SuppliesDanielle Antalffy - AnalystDrew Ranieri - AnalystJeff Johnson - Analyst ...

Stryker (NYSE:SYK) Q4 2025 Earnings call January 29, 2026 04:30 PM ET Speaker2Welcome to the fourth quarter and full year 2025 Stryker Earnings Call. My name is Layla, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that the discussions during this conference call will include for ...

| | Fourth Quarter Net Sales Growth Overview | | | | | | --- | --- | --- | --- | --- | --- | | | Foreign Currency | | Acquisitions / | | | | | Exchange Constant Currency | Reported | Divestitures | | Organic | | MedSurg and Neurotechnology | | 17.5 % 0.9 % | 16.6 % | 4.0 % | 12.6 % | | Orthopaedics | | 2.2 1.3 | 0.9 | (7.5) | 8.4 | | Total | | 11.4 % 1.0 % | 10.4 % | (0.6)% | 11.0 % | Full Year Results | | Full Year Net Sales Growth Overview | | | | | | --- | --- | --- | --- | --- | --- | | | Foreign Curren ...

核心观点 - 史赛克公司在2025年第四季度及全年实现了强劲的两位数销售和调整后每股收益增长 公司营收首次突破250亿美元 并连续第二年实现了调整后营业利润率至少100个基点的扩张 管理层对2026年的增长前景表示乐观 预计将继续在医疗器械行业的高端水平实现增长 [2][3][7] 第四季度业绩表现 - **整体销售增长强劲** 第四季度合并净销售额为71.71亿美元 同比增长11.4% 按固定汇率计算增长10.4% 有机净销售额增长11.0% 其中销量增长贡献10.9% 价格增长贡献0.1% [3][17] - **分部业绩分化明显** 医疗外科与神经技术业务销售额达45.62亿美元 同比增长17.5%（固定汇率增长16.6%） 有机增长12.6% 骨科业务销售额为26.09亿美元 同比增长2.2%（固定汇率增长0.9%） 但有机增长强劲 达到8.4% [1][4][5] - **盈利能力显著提升** 第四季度报告营业利润率为25.2% 调整后营业利润率达到30.2% 较上年同期提升100个基点 报告净利润为8.49亿美元 同比大幅增长55.5% 调整后净利润为17.26亿美元 同比增长11.6% [6][12][17] - **每股收益大幅增长** 第四季度报告摊薄每股收益为2.20美元 同比增长56.0% 调整后摊薄每股收益为4.47美元 同比增长11.5% [6][12] 全年业绩表现 - **全年营收突破250亿美元** 2025年合并净销售额为251.16亿美元 同比增长11.2% 按固定汇率计算增长10.7% 有机净销售额增长10.3% 其中销量增长贡献9.9% 价格增长贡献0.4% [2][3][17] - **分部全年增长稳健** 医疗外科与神经技术业务全年销售额达156.47亿美元 同比增长15.7%（固定汇率增长15.4%） 有机增长10.7% 骨科业务全年销售额为94.69亿美元 同比增长4.3%（固定汇率增长3.8%） 有机增长9.5% [2][4][5] - **全年利润持续改善** 2025年报告营业利润率为19.5% 调整后营业利润率为26.3% 同样扩张了100个基点 报告净利润为32.46亿美元 同比增长8.5% 调整后净利润为52.67亿美元 同比增长12.1% [6][12][17] - **全年每股收益实现双位数增长** 2025年报告摊薄每股收益为8.40美元 同比增长8.2% 调整后摊薄每股收益为13.63美元 同比增长11.8% [6][12] 业务分部与地域销售详情 - **医疗外科与神经技术业务增长引擎** 该业务增长由所有子板块驱动 其中血管业务表现尤为突出 第四季度在美国市场同比增长115.9% 全年同比增长107.5% 神经颅骨业务也表现稳健 全年增长16.3% [26][27] - **骨科业务内生增长强劲但受剥离影响** 骨科业务剔除剥离影响后的有机增长表现良好 其中膝关节（第四季度增长8.9% 全年增长8.5%）和创伤与四肢（第四季度增长9.1% 全年增长12.6%）是主要增长动力 脊柱植入物业务因剥离导致销售额大幅下滑 [5][26][27] - **美国市场是主要增长来源** 第四季度美国市场销售额增长11.7% 全年增长12.2% 国际市场增长受汇率波动影响较大 第四季度按报告增长10.6% 但按固定汇率仅增长6.3% [24] 2026年业绩展望 - **公司发布积极增长指引** 基于2025年末的增长势头、健康的手术量以及对公司资本产品的强劲需求 公司预计2026年有机净销售额增长将在8.0%至9.5%之间 调整后摊薄每股收益预计在14.90美元至15.10美元之间 [7] - **定价与汇率预期** 全年销售指引包含了轻微的有利定价影响 此外 如果汇率维持在年初至今的水平附近 预计外汇将对销售额和调整后每股收益产生略微积极的影响 [7] 财务健康状况与现金流 - **资产负债表保持稳健** 截至2025年12月31日 公司总资产为478.44亿美元 股东权益为224.20亿美元 现金及现金等价物为40.11亿美元 [19][20] - **经营活动现金流充沛** 2025年全年经营活动产生的净现金为50.44亿美元 较上年的42.42亿美元有所增长 主要得益于净利润增长以及运营资产和负债的变化 [22] - **投资活动现金流出主要用于收购** 2025年投资活动净现金流出48.66亿美元 其中用于收购的净现金支出达49.60亿美元 表明公司积极进行外部扩张 [22]

Key Takeaways SYK's Q4 performance is expected to reflect stable procedure volumes and healthy hospital capital spending.SYK likely saw broad-based demand across Orthopedics, and MedSurg and Neurotechnology, aided by new launches.SYK's margins likely gained from mix and efficiency, partly offset by tariff pressure and higher interest.Stryker Corporation (SYK) is scheduled to release fourth-quarter 2025 results on Jan. 29, after market close. In the last reported quarter, the company delivered an earnings su ...